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STRUCTURE AND DERIVATION
oric acid, also called boracic acid or orthoboric
acid, is an inorganic acid with the chemical for-
mula H3BO3. It is available as a white, odorless
powder and in crystalline and granular forms. Bo-
ric acid vaginal suppositories are not commercially
available and, therefore, must be compounded.
Most studies documenting efficacy utilize 600 mg
of boric acid powder in a gelatin capsule, although
other extemporaneous formulations have been de-
veloped,z,3
MECHANISM OF ACTION
Boric acid is a weak, topical, bacteriostatic, and fun-
gistatic agent; however, the exact mechanism of
action is unclear.4 It has been suggested that the
fungistatic activity may be mediated by vaginal
acidification, resulting in fungal cell wall penetra-
tion and disruption of the fungal cell membrane.5
Conversely, studies evaluating the minimum in-
hibitory concentration of boric acid indicate that
boric acid works at a pH similar to that of the un-
treated vaginal tract, and, therefore, the action may
not be simply due to an increase in acidity.6,7
PHARMACOKINETICS
Boric acid is rapidly and completely absorbed fol-
lowing oral ingestion and is well absorbed through
denuded and abraded skin in solution or as a dry
powder.8 Absorption has been reported to be neg-
ligible through intact skin in the presence of alka-
line salts.9 Once absorbed, boric acid is widely dis-
tributed throughout body water and accumulates in
the brain, liver, and kidneys.
8 Boric acid is not ap-
preciably metabolized and is primarily excreted un-
changed by the kidneys, with about 50% excreted
within twelve hours of administration1 and 90% of
excretion occurring within 96 hours,a Minimal
amounts are excreted in feces, sweat, and saliva,a
In a study evaluating vaginal absorption of boric
acid following the intravaginal administration of
one to two 600-mg boric acid capsules for one to
two weeks in eight healthy volunteers, daily blood
boron concentrations of less than lag/mL during
use (mean level, 42 pg/mL) were reported, lz No
volunteer had detectable boric acid levels 48 hours
after the end of treatment. Boron blood levels be-
low 200 pg/mL are thought to be safe by many
investigators, with normal blood boron levels rang-
ing from 0.1 to 80 lag/mL. z’a3 Blood boron analysis
following vaginal insertion of a single 600-mg boric
acid capsule in one healthy volunteer revealed sys-
temic boric acid absorption of approximately 6%
from the vagina and a serum half-life of about 10.5
hours. 7 A half life of 21 hours has been reported
following administration of a 600-mg intravenous
bolus to eight healthy males.a
SIDE EFFECTS AND INTERACTIONS
Short courses of intravaginal boric acid are gener-
ally well tolerated. The adverse effects reported
most frequently are mild and include watery dis-
charge, erythema, and a burning sensation; also, a
partner reported a gritty sensation with intercourse
during the treatment period,s,7,14,15 Although intra-
vaginal boric acid has been reported to be safe
when used for short periods of time, long-term
safety data is lacking. Additionally, its safety profile
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is controversial due to toxicities following ingestion
or topical exposure. In the year 1888, three cases of
acute poisoning were reported following intravagi-
nal application. 16 Other reports of vaginally admin-
istered boric acid in more than 2,000 patients reveal
an absence of toxicity. 7
The risk of systemic toxicity depends on the
concentration used, route of administration, age of
the patient, skin condition, and duration of expo-
sure. The fatal adult dose is thought to be about 20
grams or 0.1-0.5 mg/kg taken orally.
8 Boric acid
poisoning affects multiple organ systems including
the gastrointestinal tract, central nervous system
(CNS), skin, liver, and kidneys. Vomiting, diarrhea,
and abdominal pain are the most common symp-
toms. Excitement of the CNS followed by malaise,
lethargy, headache, seizures, coma, and hyperpy-
rexia also occurs. Additionally, an erythematous,
vesicular, or papular rash with desquamatization,
referred to as boiled lobster syndrome, may be ob-
served. The kidneys are probably the most seri-
ously affected of all the organs involved, resulting
in renal tubular necrosis, anuria, and albuminuria.
Death resulting from cardiovascular collapse,
shock, or respiratory failure may occur within 3-5
days of acute poisoning.8,9 The risk of systemic
toxicity due to vaginal administration of boric acid
is minimal.7
Symptoms of chronic intoxication include an-
orexia, gastrointestinal disturbances, weakness,
confusion, dermatitis, menstrual disorders, anemia,
seizures, and alopecia. No drug-drug interactions
have been reported involving boric acid.8,9
SPECTRUM OF ACTIVITY
Early reports of in vitro testing indicate that boric
acid has some activity against staphylococci and
streptococci, although the suggested action is pri-
marily bacteriostatic and slow-acting.
9 The use of
boric acid in the preservation of urine samples has
also been described. 17,18 Boric acid is most often
associated with antifungal activity, although further
elucidation is necessary. In vitro studies of boric
acid concentrations ranging from 0.4-5.0% have
been demonstrated to inhibit clinical isolates of
Candida albicans and 500 mg of boric acid has re-
portedly killed 50-90% of C. albicans isolates in 48
hours. 7’14’19 C. albicans is the most common cause of
vaginal candidiasis, although non-C, albicans spe-
cies are becoming more frequently encountered as
causative agents,z Unfortunately, azole antifungal
agents (e.g., fluconazole, itraconazole) appear to be
less effective in treating non-C, albicans species, za
Although no direct comparative trials exist, boric
acid may have improved activity against non-C, al-
bicans species.
Candida glabrata, formerly called Torulopsis gla-
brata, is the most common of the non-C, albicans
species.s,zz Many isolates of C. glabrata are resis-
tant to azole agents. Boric acid has been demon-
strated to be active against C. glabrata isolates that
are resistant to azoles, although the data is lim-
ited.5,22,23
Boric acid may also possess antifungal activity
against Saccharomyces cerevisiae, z4 Vaginitis due to
this organism is extremely rare,z4 although coloni-
zation of the respiratory and urinary tracts may oc-
cur with underlying disease.
Other non-C, albicans species against which bo-
ric acid may possess activity include Candidaparap-
silosis, Candida krusei, Candida tropicalis, and Tricho-
sporon beigelii; however, data supporting its use is
limited, and no evidence of susceptibility patterns
exist.5,za,z4 Additionally, one report suggests that
boric acid is effective in treating azole-resistant C.
albicans, z5 Borate salts have also been suggested to
inhibit replication and cytopathic effects of the her-
pes virus; however, the mechanism is not well un-
derstood,z6
CLINICAL APPLICATIONS
Boric acid vaginal suppositories should not be con-
sidered for the first-line treatment of uncompli-
cated vulvovaginal candidiasis because of insuffi-
cient efficacy data and controversies surrounding
its safety. Safety and efficacy of the azoles are well-
documented. Boric acid may be considered as an
alternative in azole-resistant monilial strains or re-
fractory cases of chronic, recurrent vulvovaginal
candidiasis.
Boric acid should not be used in pregnant
women due the risk of teratogenic effects and the
lack of data demonstrating safety, z7 No data is
available regarding the safety of boric acid in lac-
tating mothers; therefore, it should not be recom-
mended in this patient population.
Resistant Candidal Vaginitis
Several cases using boric acid for the treatment of
azole-refractory candidal vaginitis have been re-
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ported. Shinohara and Tasker5 described a case in
which a 32-year old female with advanced acquired
immunodeficiency syndrome (AIDS) and a CD4
count of 10/mm3, developed vulvovaginal candidi-
asis and thrush after nine months of daily treatment
with 100 mg of fluconazole. Cultures were positive
for C. krusei and C. glabrata that were resistant to
fluconazole. The patients symptoms were not con-
trolled by itraconazole, nystatin only minimally im-
proved her symptoms, and gentian violet topical
solution was cosmetically unacceptabl6 to the pa-
tient. Treatment with boric acid vaginal supposito-
ries, 600 mg twice daily, and 5% boric acid in lano-
lin resulted in relief of symptoms and was well
tolerated. Boric acid was not detectable in the se-
rum. Five months following the initial treatment,
the patient experienced three relapses that were
managed with two- to three-day courses of boric
acid.
A second case of fluconazole-resistant C. albicans
was described by Sobel and Vazquez.z5 A 38-year
old immunocompetent female with a three-month
history of C. albicans vulvovaginitis previously
treated with various over-the-counter topicals, ter-
conazole, and fluconazole developed C. albicans
that was resistant to fluconazole, itraconazole, and
ketoconazole. The patient received treatment with
600-mg boric acid vaginal capsules taken twice
daily for two weeks, resulting in clinical and my-
cological cure. Redondo-Lopez et al. z3 described a
case of flucytosine-resistant C. glabrata in a 30-year
old female who had received several courses of clo-
trimazole, ketoconazole, miconazole, flucytosine,
and intravenous amphotericin B without clinical or
mycological response. An immediate clinical and
mycologic cure was observed with the initiation of
vaginal boric acid capsules, 600 mg twice a day.
Following a maintenance course of boric acid for
three months, the patient remained without symp-
toms or positive culture for one year.
Vaginitis due to Saccharomyces cerevisiae
Boric acid vaginal suppositories may be useful in
the treatment of vulvovaginitis caused by Saccha-
romyces cerevisiae, although these infections are
quite rare. Sobel et al.z4 described a case of a 30-
year old female with a five-month history of recur-
rent vaginitis from which C. glabrata was isolated.
The patient failed to respond to treatment with
clotrimazole, terconazole, ketoconazole, intrave-
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nous amphotericin B, or oral flucytosine. Clinical
and mycological cure was eventually attained with
vaginal boric acid suppositories at a dose of 600 mg
daily. While still receiving boric acid, the patient
was found to be colonized with S. cerevisiae and
developed frank vulvovaginitis that improved
when the dose of boric acid was increased to 600
mg twice daily. The patient remained asymptom-
atic with boric acid maintenance therapy for six
months. Relapse following cessation of therapy was
eradicated with boric acid suppositories. Addition-
ally, the authors evaluated the susceptibility of 20
clinical isolates of S. cerevisiae, and prolonged
therapy with boric acid, 600 mg/day, was associated
with clinical resolution and mycologic resolution in
four episodes, although mycologic clearance re-
quired prolonged therapy.
Vaginitis due to Non-C. albicans Species
A retrospective review of 75 symptomatic episodes
attributed to C. glabrata conducted by Sobel and
Chaim5 reported that C. glabrata vaginal infection
was associated with a variable but low rate of re-
sponse to azole therapy, and the use of boric acid
resulted in an improved therapeutic response in
patients with symptomatic C. glabrata vaginitis.
The investigators indicated that 600 mg boric acid
administered once daily for 14 days resulted in my-
cological eradication in 77% of episodes and in
clinical cure or improvement in 81% of episodes.
In a prospective observational study evaluating
the importance of fungal cultures in patients with
symptoms of chronic vaginitis, Nyirjesy et al. zl re-
ported that 32% of isolates obtained from 77 iso-
lates were non-C, albicans. Fluconazole provided
short-term mycologic cure in only 25% of the re-
ported non-C, albicans cases, and boric acid vaginal
suppositories, 600 mg twice daily for two weeks,
achieved the highest mycologic cure rate. Spinillo
et al.z8 reported that use of boric acid to treat 12
patients with recurrent vulvovaginitis caused by C.
glabrata yielded good long-term results, with eight
patients free of recurrence at 12-month follow-up.
Boric acid has not been extensively studied as a
treatment for fungal vaginitis. Several investigators
who used boric acid therapy for C. albicans reported
cure rates of greater than 90%,7’15’29 although this is
not considered first-line therapy due to the avail-
ability of shorter, safer treatment modalities.
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COST
Self-made boric acid capsules (boric acid, USP, and
number 0 gelatin capsules) are very inexpensive,
with an average wholesale price for a two-week
course of treatment of approximately $0.30.s The
actual cost to the patient for compounded capsules
or extemporaneously prepared suppositories may
range from $10 to $25 depending on the pharmacy.
CONCLUSIONS
Boric acid should not be considered first-line treat-
ment for vulvovaginitis due to C. albicans as more
safe, effective, and shorter duration treatment mo-
dalities are available. It may useful, however, in the
treatment of chronic recurrent vulvovaginal candi-
diasis due to azole-resistant strains or treatment
failures.
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